This website is intended for healthcare professionals only

touchNEUROLOGY

Search

Trending Topic

Developed by Touch

European Stroke Organisation Conference 2026: Expanding the boundaries of acute stroke care

Federica Rizzo, Ettore Nicolini, Antonio Ciacciarelli

The 12th European Stroke Organisation Conference (Maastricht, May 6–8, 2026) was dominated by studies testing the limits of acute stroke therapy, from thrombectomy and neuroprotection to secondary prevention. Supplementary Table 1 provides a comprehensive overview of the major studies presented during the conference. The large-core indication for thrombectomy is recent, and the ATLAS (Endovascular thrombectomy […]

touchREVIEWS in Neurology. 2026;22(1):Online ahead of journal publication

Multiple Sclerosis

EAN 2016 Celia Oreja Guevara Interview

Published Online: Jun 30th 2016

Celia Oreja-Guevara reviews the most exciting developments in MS therapy over the last year.

Trending Topic

Developed by Touch

The evolving role of the MS nurse: MS Toronto 2026

Kathleen Costello, Bonnie Blain

Kathleen Costello and Bonnie Blain discuss how increasing complexity in multiple sclerosis care is reshaping the role of nurses, the challenges facing the global MS nursing workforce, and what attendees can expect from the nursing program at MS Toronto 2026. touchNEUROLOGY coverage of MSToronto 2026 Ahead of MS Toronto 2026, touchNEUROLOGY spoke with […]

Related Videos in Multiple Sclerosis

Developed by Touch

Simon Faissner, EAN 2023: Safety and efficacy of diroximel fumarate in older patients with multiple sclerosis from the phase III EVOLVE-MS-1 study

Oral diroximel fumarate (DRF) has similar efficacy/safety to dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), but improved GI tolerability. In the from EVOLVE-MS-1 study, safety/efficacy of DRF was assessed in patients with RRMS aged >=55 years. Dr Simon ...

Developed by Touch

Enrique Alvarez, AAN 2023: Disease outcomes with ublituximab in participants with highly active disease from subpopulation analyses of the phase III ULTIMATE I and II studies in participants with relapsing multiple sclerosis

The phase III clinical studies Ultimate I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) ...

Developed by Touch

Enrique Alvarez, AAN 2023: Ublituximab for participants with relapsing multiple sclerosis

The phase III clinical studies ULTIMATE I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) ...

Developed by Touch

Highlights from EAN 2023!

...

Developed by Touch

Barry Singer, ECTRIMS 2022: Diroximel fumarate for relapsing-remitting multiple sclerosis - Phase 3 results from EVOLVE-MS-1

The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the ...

Developed by Touch

Barry Singer, ECTRIMS 2022: Flushing and GI adverse events in RRMS patients on diroximel fumarate - Analysis from phase 3 EVOLVE-MS-1 study

The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the ...

Dominic Shadbolt: ECTRIMS Patient perspective - Lifestyle interventions as part of a management plan for MS

We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. ...

Developed by Touch

Dominic Shadbolt: ECTRIMS Patient perspective - Technologies and tools to predict patient outcomes in MS

We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. ...

Developed by Touch

Dominic Shadbolt: ECTRIMS Patient perspective - The importance of early intervention in MS

We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. ...

Developed by Touch

Georgina Arrambide, ECTRIMS 2022: Serum neurofilament light chain (sNfL) Z score cut-offs in multiple sclerosis

Serum neurofilament light chain (sNfL) levels in MS are associated with inflammatory activity and less clearly with disability. In this touchNEUROLOGY interview, we caught up with Dr Georgina Arrambide (Cemcat, Vall d´Hebron University Hospital, Barcelona, Spain) to discuss the ...

Nele Handwerker: Living with MS – living life to the full

Ms Nele Handwerker is living with multiple sclerosis (MS), and is a patient advocate. She joins us for World Brain day and shares the story of her MS diagnosis. Nele discusses strategies and resources that she believes could help improve ...

Developed by Touch

Barbara Willekens, EAN 2022: Predictors of disease progression and outcome in multiple sclerosis - Highlights

Cognitive impairment can predict physical disability progression in multiple sclerosis (MS). It was a pleasure to speak with Dr Barbara Willekens (Antwerp University Hospital, Edegem, Belgium), who talked through some of the presentations given in this EAN 2022 session on predictors ...

Latest articles videos and clinical updates - straight to your inbox

Sign Up

Login

Sign Up FREE

Log into your Touch Account

Keep track of your clinical interests and newsletter subscriptions.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Sign up with an Email

Sign up with Google

Sign up with Facebook

Sign up with LinkedIn

Sign up with Microsoft

Already have an Account?

Login

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

Register now for FREE access

Already registered? Login below.

Register

Login